NOVOCURE LIMITED

(NVCR)
  Report
Delayed Nasdaq  -  04:00 2022-08-17 pm EDT
82.25 USD   -0.96%
08/10Novocure Hosts U.S. Sen. Maggie Hassan at Company's Portsmouth Facility
BU
08/04INSIDER SELL : Novocure
MT
07/29Truist Securities Drops NovoCure's Price Target to $105 From $118, Keeps Buy Rating
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Novocure Enrolls First Patient in KEYNOTE-B36, a Pilot Study of Tumor Treating Fields Together with KEYTRUDA® for Patients with First-Line Stage III Non-Small Cell Lung Cancer

06/21/2022 | 08:00am EDT

Novocure announced the first patient has been enrolled in its phase 2 pilot KEYNOTE-B36 study, conducted in collaboration with MSD, a tradename of Merck & Co. Inc., Rahway, NJ, USA. KEYNOTE-B36 is designed to evaluate the safety and effectiveness of Tumor Treating Fields (TTFields) together with KEYTRUDA® (pembrolizumab), MSD's anti-PD-1 therapy, for the first-line treatment of locally advanced or metastatic intrathoracic non-small cell lung cancer (NSCLC) that expresses PD-L1. KEYNOTE-B36 is a single arm, open-label phase 2 pilot study expected to enroll 66 patients. The primary endpoint of the study is objective response rate. Secondary endpoints include overall survival, progression free survival (PFS), PFS at six months, one-year survival rate, duration of response, disease control rate and frequency and severity of adverse events.


© S&P Capital IQ 2022
All news about NOVOCURE LIMITED
08/10Novocure Hosts U.S. Sen. Maggie Hassan at Company's Portsmouth Facility
BU
08/04INSIDER SELL : Novocure
MT
07/29Truist Securities Drops NovoCure's Price Target to $105 From $118, Keeps Buy Rating
MT
07/29Piper Sandler Adjusts NovoCure's Price Target to $90 From $100, Reiterates Overweight R..
MT
07/28NovoCure Q2 Loss Widens, Net Revenue Rises
MT
07/28TRANSCRIPT : NovoCure Limited, Q2 2022 Earnings Call, Jul 28, 2022
CI
07/28NOVOCURE : Q2 Earnings Snapshot
AQ
07/28NOVOCURE : Quarterly net revenues of $140.9 million, a 6% increase year-over-year - Form 8..
PU
07/28Novocure Reports Second Quarter 2022 Financial Results
BU
07/28NOVOCURE LTD Management's Discussion and Analysis of Financial Condition and Results o..
AQ
More news
Analyst Recommendations on NOVOCURE LIMITED
More recommendations
Financials (USD)
Sales 2022 547 M - -
Net income 2022 -86,5 M - -
Net Debt 2022 113 M - -
P/E ratio 2022 -105x
Yield 2022 -
Capitalization 8 615 M 8 615 M -
EV / Sales 2022 16,0x
EV / Sales 2023 15,0x
Nbr of Employees 1 167
Free-Float 86,7%
Chart NOVOCURE LIMITED
Duration : Period :
NovoCure Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVOCURE LIMITED
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 8
Last Close Price 82,25 $
Average target price 94,25 $
Spread / Average Target 14,6%
EPS Revisions
Managers and Directors
Asaf Danziger Chief Executive Officer & Director
Ashley Cordova Chief Financial Officer
William F. Doyle Executive Chairman
Uri Weinberg Chief Science Officer
Ely Benaim Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
NOVOCURE LIMITED9.55%8 615
SHOCKWAVE MEDICAL, INC.58.95%10 416
MASIMO CORPORATION-43.46%8 898
PENUMBRA, INC.-41.46%6 430
GETINGE AB-43.10%5 918
ASAHI INTECC CO., LTD.9.79%5 488